Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637252 | 0.84 | PDE4A (0.60) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL751651 | 0.84 | CA1 (0.51) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2995451 | 0.81 | PDE4A (0.62) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL3967067 | 0.81 | PDE4A (0.54) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2462620 | 0.81 | PDE4B (0.51) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7435222 | 0.80 | PDE4A (0.55) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2988958 | 0.80 | PDE4A (0.63) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL4637671 | 0.80 | PDE4A (0.61) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2989802 | 0.79 | PDE4A (0.61) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL8285881 | 0.79 | PDE4A (0.59) | PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263637-B2 | Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | CELGENE CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110038832-A1 | METHOD FOR TREATMENT OF MACULAR DEGENERATION USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | CELGENE CORPORATION | 2011-02-17 | — | — | US | disclosed |
| EP-2258363-A1 | Compositions for treatment of cancers | CELGENE CORPORATION (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7842691-B2 | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2010-11-30 | — | — | US | disclosed |
| US-7776907-B2 | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide | CELGENE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1242082-B1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2036553-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | CELGENE CORPORATION (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2016942-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORPORATION (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080096952-A1 | Methods for the treatment of atherosclerosis, using substituted phenethylsulfones | CELGENE CORPORATION | 2008-04-24 | — | — | US | disclosed |
| EP-1538913-A2 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORPORATION (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050118715-A1 | Modulation of stem and progenitor cell differentiation, assays, and uses thereof | Celularity, Inc. | 2005-06-02 | — | — | US | disclosed |
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | CELGENE CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003087333-A2 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1242082-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020054899-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORP. | 2002-05-09 | — | — | US | disclosed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6020358-A | REDUCING TUMOR NECROSIS FACTOR CONCENTRATION | CELGENE CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| US-6011050-A | Substituted phenethylsulfones and method of reducing TNFα levels | CELGENE CORPORATION (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | IL2, IL6, IL1B | PDE4A 295/4885PDE4B 348/4885PDE4D 487/4885 |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | IL2, HDGF, VEGFA | PDE4A 1843/4885PDE4B 1724/4885PDE4D 2450/4885 |
| US-20080096952-A1 | Methods for the treatment of atherosclerosis, using substituted phenethylsulfones | TNF, TGFB1, TGFB2 | PDE4A 2291/4885PDE4B 2615/4885PDE4D 3609/4885 |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | IL6, IL2, IL6ST | PDE4A 498/4885PDE4B 561/4885PDE4D 921/4885 |
| US-20050118715-A1 | Modulation of stem and progenitor cell differentiation, assays, and uses thereof | PGF, MYADM, ALPP | PDE4A 1010/4885PDE4B 992/4885PDE4D 1139/4885 |
| US-20110038832-A1 | METHOD FOR TREATMENT OF MACULAR DEGENERATION USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | ALDH1A2, MTNR1A, MTNR1B | PDE4A 243/4885PDE4B 438/4885PDE4D 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.